Pharma
The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders and engineers.
Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and possibly at less expense.
uMed’s registry platform will work alongside WellSky’s network of home-based care organizations to let patients participate in national clinical trials from home.
During a fireside chat with Scripta Insights’ CEO, Cuban discussed TrumpRx and unveiled new MCCPDC innovations, including mobile drug-making pods and the Cost Plus Wellness network.
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
The funds will be used to bolster AI and computational physics-based model development for numerous modalities.
The company will use the funds to add on more specialties and invest in an AI-enabled pharmacy management system.
The company helps match patients to relevant clinical trials and engages in recruitment for biopharma partners.
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.
The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.